SON-1210
Solid Tumors (Pancreatic Cancer)
Phase 1/2aActive
Key Facts
About Sonnet BioTherapeutics
Sonnet BioTherapeutics is a clinical-stage biotech focused on developing targeted immunotherapies using its proprietary Fully Human Albumin-Binding (FHAB™) technology platform. Its mission is to improve the safety and efficacy of cytokine therapies for cancer and peripheral neuropathies by leveraging the body's natural albumin transport system. A key strategic achievement was the December 2025 business combination with Hyperliquid Strategies Inc., creating a Nasdaq-listed entity (PURR) with a dual operational model combining biotech R&D with digital asset treasury management. The company's strategy centers on advancing its modular pipeline through internal development and strategic collaborations.
View full company profile